Ruben Krupik - Chairman of the Board of Directors

Mr. Krupik has served as a director and Chairman of the Board since March 2011. He is the Chief Executive Officer of Clal Biotechnology Industries, and is a central figure in the strategic advancement of companies in Israel's biomed industry. He is the Chairman of D-Pharm Ltd. (TASE: DPRM), CureTech Ltd., MediWound Ltd., Gamida Cell and Andromeda Biotech. An accomplished, multi-disciplinary industry executive, Mr. Krupik has been a key driver in the launch of numerous successful companies in the fields of medical technology, including Given Imaging (NASDAQ:GIVN). Mr. Krupik held several senior positions at Tadiran Telecommunication Group where he accrued extensive experience in high-tech management. He holds an LL.B. from Tel Aviv University and a B.A. in economics and political science from the Hebrew University of Jerusalem.

Prof. Avraham Hochberg, Ph.D.

Prof. Hochberg has served as a director since March 2006, and was our Chairman between 2006 and 2009. He served in the Israeli Defense Forces, reaching the rank of Lieutenant-Colonel. He received his Ph.D. summa cum laude from the Hebrew University of Jerusalem, Israel, and has been a member of the academic faculty for over 50 years. He has served as our Chief Scientist since inception in 2004. A biochemist and molecular biologist in the Department of Biological Chemistry at the University, Prof. Hochberg is recognized as a world-leading expert on the H19 gene, which plays a significant role in the tumor development process by enabling tumor cells to survive under stress conditions. He led the 19-year ground-breaking research that led to the development of BC-819. His list of around 150 publications covers seminal contributions in the fields of imprinted genes, the H19 gene, IGF2 gene and oncology. He also holds a B.A. in Archaeology.

Mr. Aviv Boim

Mr. Boim has served as a director since July 2008. He is the Chief Executive Officer of Tikcro Technologies, Ltd., which he joined from Orckit Communications Ltd., where he held the position of Chief Financial Officer for nearly ten years. Prior to joining Orckit, Mr. Boim was a banker with BT Alex. Brown Incorporated, an investment banking firm. Mr. Boim holds a B.A. and an M.A. in economics and management from Tel Aviv University and an L.L.B. from Tel Aviv University Law School.

Mr. Ofer Goldberg

Mr. Goldberg has served as a director between April 2007 and October 2009, and since March 2011. He is a Vice President at Clal Biotechnology Industries, and is involved in the business strategy and development of technology of CBI's portfolio companies. He was previously an analyst and equity funds manager. Mr. Goldberg serves on boards of directors of a number of biomed companies, including D-Pharm Ltd. (TASE: DPRM), Biokine Therapeutics Ltd., ProtAb Ltd., Vacciguard Ltd and Iluten Ltd. He holds an M.A. in Economics and Finance from Tel Aviv University and a B.Sc. in Physics and Mathematics from the Hebrew University of Jerusalem.

Mr. Hanoch Rappaport

Mr. Rappaport has served as a director since January, 2006. He is the CFO of the Provident Fund of the Employees of the Hebrew University, Ltd., and previously served as Investment Manager at A. Heifetz & Co., where he was responsible for the investment process, monitoring portfolio companies and maintaining liaison with a network of private and institutional investors. Prior to that, he was a corporate credit officer at Israel's Bank Hapoalim. Mr. Rappaport holds a B.A. in Economics and Political Science from Bar-Ilan University, an MBA from the Tel Aviv International School of Management and an MBA in Finance from the Hebrew University of Jerusalem, Israel.

Mr. David Schlachet

Mr. Schlachet has served as a director since January 2010. He was previously CEO of Syneron Medical Ltd., Managing Partner of Biocom (a venture capital fund specializing in the life sciences area), senior VP and CFO of Strauss Elite Holdings, VP Finance & Administration of the Weizmann Institute of Science, and CEO of the Weizmann Institute's technology transfer company, Yeda R&D Co. Ltd. Mr. Schlachet holds a B.Sc. in chemical engineering from the Technion, and an MBA (Finance) from the Tel Aviv University.

Ms. Orly Yarkoni

Ms. Yarkoni has served as a director since January 2010. She has amassed over 20 years in the insurance industry, most recently as CEO of IDI (Direct Insurance), Ltd. She has served as a member of the Board of Governors of the Israeli Securities Authority, and currently serves as a director of Peninsula Finance, Ltd., Menorah Mivtachim Insurance, Ltd., Ma'ayanot Eden, Ltd., Plasto-Sac, Ltd. and Amot Investments, Ltd. Ms. Yarkoni holds a B.Sc. (cum laude) in Mathematics from the Hebrew University of Jerusalem, Israel, and is a member of the Israeli Association of Actuaries.